Payment overview · 2025
General Payments
$289.76
4 reported records · 3 companies
Healthcare provider profile · identity verified
Edgar Camargo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SALTVILLE, VA · NPI 1235112558
Verified facts
What the public records show
CMS Open Payments records show Edgar Camargo, M.D. received $289.76 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.30 | 43.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $125.00 | 43.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.46 | 13.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $289.76 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.30 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.46 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
43 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 409 | 99 |
| Gabapentin | Gabapentin | 395 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 342 | 82 |
| Omeprazole | Omeprazole | 337 | 78 |
| Lisinopril | Lisinopril | 317 | 95 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 58 |
| Furosemide | Furosemide | 231 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 52 |
| Baclofen | Baclofen | 165 | 45 |
| Valsartan | Valsartan | 161 | 39 |
| Tramadol Hcl | Tramadol Hcl | 156 | 24 |
| Trazodone Hcl | Trazodone Hcl | 151 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 45 |
| Montelukast Sodium | Montelukast Sodium | 134 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 22 |
| Metformin Hcl | Metformin Hcl | 127 | 39 |
| Losartan Potassium | Losartan Potassium | 124 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 24 |
| Potassium Chloride | Potassium Chloride | 118 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 110 | 24 |
| Jardiance | Empagliflozin | 109 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 22 |
| Atenolol | Atenolol | 95 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 22 |
| Metformin Hcl Er | Metformin Hcl | 92 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 35 |
| Eliquis | Apixaban | 88 | 17 |
| Prednisone | Prednisone | 88 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 24 |
| Meclizine Hcl | Meclizine Hcl | 85 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 19 |
| Carvedilol | Carvedilol | 79 | 25 |
| Chlorthalidone | Chlorthalidone | 77 | 20 |
| Simvastatin | Simvastatin | 77 | 21 |
| Glimepiride | Glimepiride | 76 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 15 |
| Sertraline Hcl | Sertraline Hcl | 73 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 24 |
| Meloxicam | Meloxicam | 65 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 63 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 16 |
| Pregabalin | Pregabalin | 62 | suppressed |
| Ibuprofen | Ibuprofen | 61 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Januvia | Sitagliptin Phosphate | 58 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 55 | suppressed |
| Famotidine | Famotidine | 51 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Ezetimibe | Ezetimibe | 45 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 15 |
| Spironolactone | Spironolactone | 44 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | 19 |
| Allopurinol | Allopurinol | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Loperamide | Loperamide Hcl | 40 | suppressed |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Ibu | Ibuprofen | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Glipizide | Glipizide | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Abilify Maintena | Aripiprazole | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $289.76 · 4 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error